Sort
82,697 grants matching “vaccine development”
Mechanisms of protection against shigellosis in children
$764,815Marcela F Pasetti · University Of Maryland Baltimore · R01 · FY2023 · AI
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of Insulin
$764,792Omid C Farokhzad · Brigham And Women'S Hospital · R01 · FY2012 · EB
Multivalent nanocluster universal influenza vaccine given by microneedle patch
$764,738Baozhong Wang · Georgia State University · R01 · FY2020 · AI
Immune Responses Associated with Malaria Infection and Immune Protection - Project 1
$764,617Kenneth D Stuart · Seattle Children'S Hospital · U19 · FY2021 · AI
Development of a Universal Vaccine Against Leptospirosis
$764,616Elsio Augusto Wunder · University Of Connecticut Storrs · R01 · FY2025 · AI
Baltimore Acute Hepatitis C Cooperative Center
$764,565Andrea L Cox · Johns Hopkins University · U19 · FY2010 · AI
Development of a lyophilized intradermal/intranasal ricin vaccine
$764,532Ellen S Vitetta · Ut Southwestern Medical Center · U01 · FY2006 · AI
HIV-1 Genetic Variation in Infected Individuals
$764,520Frank Maldarelli · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Sinusitis in Children and the Nasopharyngeal Microbiome
$764,517Ellen R. Wald · University Of Wisconsin-Madison · R01 · FY2012 · AI
Generation of a Complete Set of Precise Null Bar-Coded Deletion Mutants of Mycobacterium tuberculosis
$764,494William Robert Jacobs · Albert Einstein College Of Medicine · R24 · FY2023 · AI
Elucidating Genetic Determinants of Resistance to Lassa Hemorrhagic Fever
$764,463Pardis Christine Sabeti · Broad Institute, Inc. · R01 · FY2015 · AI
CCR5-mutant monkey model to facilitate the development of novel stem cell-based therapies for AIDS
$764,417Igor I Slukvin · University Of Wisconsin-Madison · R24 · FY2016 · OD
Initiation of immune responses to SARS COV2 in the oral cavity and upper airway
$764,413Sarah C Glover · Tulane University Of Louisiana · R01 · FY2023 · DE
Developing capsid-importin alpha inhibitors for the treatment of VEEV infection
$764,337Mikell Paige · George Mason University · R01 · FY2020 · AI
Allergen Loaded Nanoparticles for Food Allergy Tolerance
$764,326Lonnie D Shea · University Of Michigan At Ann Arbor · R01 · FY2021 · AI
Chemoenzymatic glycan editing for deciphering biological functions of glycans
$764,241Peng Wu · Scripps Research Institute, The · R35 · FY2023 · GM
Chemoenzymatic glycan editing for deciphering biological functions of glycans
$764,241Peng Wu · Scripps Research Institute, The · R35 · FY2022 · GM
Novel delivery platform and antigen design for an effective COVID-19 vaccine
$764,234Suresh K Mittal · Purdue University · R01 · FY2023 · AI
Conjugate vaccine impact on pneumococcal carriage, disease, and population geneti
$764,153Jonathan A Finkelstein · Harvard Pilgrim Health Care, Inc. · R01 · FY2012 · AI
RNA Metabolism in Trypanosomes
$764,100Christian Tschudi · Yale University · R01 · FY2018 · AI
Vector-borne pathogen transmission
$764,039Shaden Kamhawi · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
MHC-bound, SIV-derived, CTL and HTL Epitopes
$763,872David I Watkins · University Of Wisconsin-Madison · R24 · FY2011 · RR
Elucidating the biological mechanisms underlying the association between EBV and MS in African Americans
$763,865Alberto Ascherio · Harvard University D/B/A Harvard School Of Public Health · R01 · FY2025 · AI
QUALITY ASSURANCE/ QUALITY CONTROL (QA/QC)
$763,839Ranajit Pal · Advanced Bioscience Laboratories, Inc. · N01 · FY2017 · AI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex
$763,782Andrew McGuire · Fred Hutchinson Cancer Center · R01 · FY2022 · AI